Reading BRKR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BRKR free→Reading BRKR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BRKR free→QuarterlyIQ Insights · BRKR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on May 14, 2026, and is payable July 7, 2026, to shareholders of record at the close of business on June 22, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly a…
Results of Operations and Financial Condition. On May 6, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…
Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share, of $3.9844 per share. The dividend was declared on April 28, 2026, and is payable June 1, 2026, to shareholders of record at the close of business on May 15, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 6, 2026, Bruker Corporation (the “Company”) and Falko Busse, Ph.D., an executive officer of the Company and President of the Bruker BioSpin Group (“Bruker BioSpin”), a wholly owned subsidiary of the Company, agreed that his duties as executive officer with the Company and as President of Bruker BioSpin would transition on or around May 1,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Election of New Director On March 27, 2026, the Board of Directors (the “Board”) of Bruker Corporation (the “Company”) approved an increase in the number of directors to expand the size of the Board by one director to a total of twelve directors, with such additional director assigned to Class III, and appointed Thierry L. Bernard to fill the n…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retirement of Director On February 16, 2026, Dr. Cynthia M. Friend informed the Board of Directors (“Board”) of Bruker Corporation (the “Company”) of her decision not to stand for re-election as a Class II director when her current term expires at the Company’s 2026 Annual Meeting of Stockholders (“2026 Annual Meeting”). Dr. Friend’s decision is no…
Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on February 19, 2026, and is payable April 7, 2026, to shareholders of record at the close of business on March 23, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto…
Results of Operations and Financial Condition. On February 12, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'expensive' to 'full'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.